Theraclion SA

Regulatory Filings • Jul 2, 2015

First Echopulse reference site in Asia: The University of Hong Kong awards tender to Theraclion

The University of Hong-Kong's Queen Mary Hospital will offer non-invasive ablation of breast fibroadenoma and benign thyroid nodules

Malakoff – July 2, 2015 – THERACLION (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, today announced that it has been awarded the tender for an Echopulse system in the Queen Mary Hospital, Hong-Kong, China. The hospital will be Theraclion's first reference site for the Asian market for both breast fibroadenoma and benign thyroid nodule treatments.

In China alone, an estimated 740,000 women per year with breast fibroadenoma receive some form of treatment. Surgery is the most common treatment but minimally-invasive techniques are a relatively common alternative. Each year, China has at least 50 million cases of thyroidrelated problems and, although a great majority remain undiagnosed, surgical intervention is very common.

"The non-invasive nature of Echopulse treatment, as well as the fact that Echopulse requires no general anesthesia or hospitalization is a major advantage," says Sylvain Yon, Deputy CEO of Theraclion. He adds, "for the treatment of breast fibroadenoma and thyroid nodules, noninvasive treatment is the next obvious step after the adoption of minimally-invasive techniques, which are well developed in Asia."

The University of Hong-Kong is among the 3 best ranked universities in the Times Higher Education Asia University Rankings 2015. "This first reference center is a milestone in the development of the Asian market for us. We are currently engaged in advanced discussions with strategic partners in the most significant countries where the CE mark is accepted and where echotherapy can be a transforming solution," says David Caumartin, CEO of Theraclion.

About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 25 people, 52 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: www.theraclion.com.

Theraclion is listed on Alternext Paris PEA-PME Eligible Mnemonic: ALTHE - ISIN Code: FR0010120402

Contacts:

Theraclion NewCap Tel.: +33 (0)1 55 48 90 70 Tel.: +33 (0)1 44 71 94 94 david.caumartin@theraclion.com theraclion@newcap.fr

Kalima

Press Relations Estelle Reine-Adélaïde/ Florence Calba Tel. : + 33 (0)1 44 90 82 54 era@kalima-rp.fr

David Caumartin Financial Communications & Investors relations CEO Emmanuel Huynh / Valentine Brouchot